Pharmaceuticals

Evotec has received a takeover offer from Halozyme, potentially creating a major player in life sciences. Retail investors should watch for market...

Natera's impressive Q3 2024 highlights its strong position in the genetic testing market.

Fungal outbreaks are increasing globally, impacting health systems and creating new investment opportunities in antifungal research and treatments.

Learn how specialty ingredients leader Ingredion is driving growth and targeting new markets in the consumer staples sector.

Bristol Myers Squibb's Cobenfy, the first new schizophrenia treatment in over 70 years, offers hope for patients and investment potential for the...

See how Viridian Therapeutics (NASDAQ: VRDN) is innovating thyroid eye disease treatments with advanced therapies and a growing market opportunity.

Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors...

Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's...

Discover the financial impact of rising GLP-1 medication usage on employer healthcare costs and its relevance for retail investors.

Discover why Johnson & Johnson's $6.48 billion talc settlement matters for retail investors: stock impact, legal risks, governance insights,...

CARGO Therapeutics reported Q2 2024 results with a slight EPS miss and higher-than-expected R&D expenses, while maintaining a strong cash position.

Novo Nordisk faces stock drop and competition pressures. Revenue growth vs. profit forecast. Political scrutiny and market strategy in focus.

Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.

Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.

Embecta Corp, the top insulin pen needle producer, eyes a sale after a 70% share price drop post-spin-off.

Sarepta Therapeutics Inc (NASDAQ: SRPT) achieves FDA approval for its gene therapy for Duchenne muscular dystrophy in patients aged four and older.